Reader TTS

The recent research published in _The New England Journal of Medicine_ by Y. Doki et al. has reported the interim findings from the CheckMate 648, which is an international, multi-center,

open-label, and randomized phase 3 clinical trial to explore the role of dual immune checkpoints inhibitors combination for patients with advanced esophageal squamous cell carcinoma (ESCC)1.

This study evaluated the efficacy and safety of the combination of PD-1 and CTLA-4 inhibitors for patients with advanced ESCC, aiming to provide some enlightenment for advanced ESCC

treatment. Patients recruited in the CheckMate 648 were diagnosed with advanced, metastatic, or recurrent ESCC. The details of enrollment criterion included age more than 18-year, naïve to

systemic therapy for advanced disease, measurable disease, pathological identification of ESCC or esophageal adenosquamous carcinoma. All 970 patients were randomly divided into nivolumab

plus chemotherapy, nivolumab plus ipilimumab, and chemotherapy alone groups for 1:1:1. The primary endpoints included progression-free survival (PFS) and overall survival (OS), while

objective response rate was the secondary endpoint. Compared with the chemotherapy alone group (median PFS: 5.6 months, median OS: 10.7 months), the nivolumab plus chemotherapy group

demonstrated longer PFS (median PFS: 5.8 months) and OS (median OS: 13.2 months) in all populations, and the nivolumab plus ipilimumab groups exhibited favorable OS (median OS: 12.7 months)

in all populations, however, only patients with PD-L1 expression ≥1% achieved significantly longer median duration of response than chemotherapy group (11.8 months vs. 5.7 months). For

safety, the occurrence of grade 3 and higher-level treatment-related adverse was 36%, 47%, and 32% in the chemotherapy alone, nivolumab plus chemotherapy, and nivolumab plus ipilimumab

groups, respectively. The combination group suggested acceptable toxicity for participants. In China, ESCC is one of the most common digestive tumors, accounting for about 90% of cases

worldwide. Most patients have progressed to advanced disease by the time of diagnosis, losing the opportunity for surgical resection, with an unfavorable survival. The monotherapy combined

with chemotherapy achieved significant survival benefits for patients with ESCC2. However, the adverse effects related to chemotherapy are difficult matters in clinical. The dual immune

checkpoints inhibitors regimen exhibited synergistic anti-tumor effects in cancers, with higher objective response rates and better clinical outcomes than PD-1 inhibitor alone, as well as a

manageable toxicity profile (Table 1). Researchers are thinking about whether this regimen can be used in advanced ESCC for the purpose of de-chemotherapy. In this study, the role of the

nivolumab plus ipilimumab regimen was firstly explored in advanced ESCC treatment. Compared to previous dual inhibitors trials involved in esophageal cancer (Checkmate 032 of metastatic

esophagogastric cohort), this study enrolled a considerable number of participants and provided more reliable evidence to support the potential efficacy of this dual inhibitors combination,

which is also consistent with the results of Checkmate 032. This study also achieved comprehensive subgroup analyses to identify the potential biomarker (PD-L1) of response to this dual

inhibitors regimen. The study exhibited promising results, especially in patients with PD-L1 expression ≥1%. Unfortunately, patients with negative PD-L1 expression seemed to benefit little

from this combination, and a constant follow-up is needed to observe whether patients with negative PD-L1 will eventually benefit from this regimen. Therefore, chemotherapy still has a

proper place in the treatment of advanced ESCC, especially PD-1 inhibitor combined with chemotherapy is the most widely applied treatment. It is worthwhile to consider whether the

combination of chemotherapy with dual inhibitors can enhance the responses of patients, especially those patients with negative PD-L1, with manageable toxicities. The authors failed to

explore more subgroups analyses except for PD-L1. Previous studies have observed patients with blood-Tumor burden mutation (bTMB) ≥20 mut/Mb or high TMB regardless of PD-L1 expression

significantly benefited from the PD-L1 plus CTLA-4 inhibitors in lung cancer3,4. In metastatic colorectal cancer, patients with microsatellite instability-high/mismatch repair-deficient

(MSI-H/dMMR) demonstrated a durable clinical benefit from this dual inhibitors regimen5. We speculated that bTMB, TMB, and MSI-H/dMMR may be potential biomarkers of this combination in

advanced ESCC. The robust biomarkers are warranted to select patients sensitive to dual inhibitors, maximizing their survival benefits and avoiding serious adverse effects of chemotherapy.

Moreover, whether this dual immune checkpoint blockades regimen can be applied to the other treatment period of ESCC, for example, as neoadjuvant therapy to improve pathological complete

rates for patients with PD-L1 expression ≥1%, or higher bTMB and TMB, or MSI-H/dMMR? Novel anti-tumor drugs are being vigorously developed. In the future, we believe that newly developed

drugs may be available in combination with current immune checkpoint inhibitors to help patients with ESCC achieve a favorable prognosis and quality of life without chemotherapy. To improve

the outcome of patients with advanced ESCC, we need to take a two-pronged approach. Firstly, we need to examine the role of potential therapy regimens in the efficacy of ESCC with a view to

finding the most promising treatment modalities. Secondly, since the tumor microenvironment varies greatly among patients with ESCC, the same treatment suggests different efficacy in

different patients. It is essential to select individualized treatments for every patient. Whether it is an immunotherapy plus chemotherapy regimen, a dual immunotherapy combination, or a

novel option in the future, how to apply these regimens to the appropriate patients is a major concern. The robust biomarkers are warranted to help us screen out the most appropriate

patients for different regimens, which achieve a favorable prognosis and avoid unnecessary side effects for patients with ESCC. The patient’s physical tolerance and contraindications to

treatments should also be considered. Personalized treatment and management have been the primary clinical concern for ESCC, which needs to be continuously improved. Improving the clinical

outcomes of advanced ESCC has been a formidable challenge. The results of CheckMate 648 comprehensively uncovered the function of nivolumab plus ipilimumab combination in advanced ESCC,

which is a novel attempt at the de-chemotherapy regimen. Although this dual immunotherapy did not suggest very promising achievements in all populations, it still has favorable efficacy in

patients with PD-L1 expression ≥1%. The findings provided valuable insights into the clinical management of advanced ESCC. REFERENCES * Doki, Y. et al. Nivolumab combination therapy in

advanced esophageal squamous-cell carcinoma. _N. Engl. J. Med._ 386, 449–462 (2022). Article  CAS  Google Scholar  * Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy

alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. _Lancet_. 398, 759–771 (2021). Article  CAS  Google Scholar  *

Rizvi, N. A. et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical

trial. _JAMA Oncol._ 6, 661–674 (2020). Article  Google Scholar  * Hellmann, M. D. et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in

small-cell lung cancer. _Cancer Cell._ 33, 853–861.e854 (2018). Article  CAS  Google Scholar  * Lenz, H. J. et al. First-line Nivolumab plus low-dose ipilimumab for microsatellite

instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. _J. Clin. Oncol._ 40, 161–170 (2022). Article  CAS  Google Scholar  Download

references ACKNOWLEDGEMENTS This work was supported by the Fundamental Research Funds for the Central Universities (3332018070), the National Key Basic Research Development Plan

(2018YFC1312105), and the Beijing Natural Science Foundation (J20010). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Thoracic Surgery, National Cancer Center/National Clinical

Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China Yuejun Luo, Nan Sun & Jie He * State Key

Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,

Beijing, China Yuejun Luo, Nan Sun & Jie He Authors * Yuejun Luo View author publications You can also search for this author inPubMed Google Scholar * Nan Sun View author publications

You can also search for this author inPubMed Google Scholar * Jie He View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHORS Correspondence

to Nan Sun or Jie He. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. INFORMED CONSENT All authors approve the manuscript for publication. RIGHTS AND

PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any

medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The

images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not

included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly

from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Luo, Y., Sun, N.

& He, J. Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC. _Sig Transduct Target Ther_ 7, 169 (2022). https://doi.org/10.1038/s41392-022-01022-x

Download citation * Received: 28 March 2022 * Revised: 28 April 2022 * Accepted: 06 May 2022 * Published: 25 May 2022 * DOI: https://doi.org/10.1038/s41392-022-01022-x SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative